Kornimate/medical-research-clean huggingface dataset:
post-radioiodine graves' management: the pragma-study

Conditions: Graves' Disease

Summary: thyroid dysfunction following radioiodine for graves' disease is common, potentially detrimental and avoidable. a variety of clinical strategies are employed in the post-radioiodine era util the patient is on a stable thyroid hormone replacement regimen, which include the use of anti-thyroid drugs, antithyroid drugs with thyroxine, early thyroxine replacement and watchful monitoring until the onset of hypothyroidism. which of these is most effective in avoiding dysthyroidism, is unknown. this study aims to address this lack of evidence. it will focus on graves' disease as this is the commonest cause of thyrotoxicosis and the commonest indication for ri therapy. it will provide an insight into potential strategies for improving important clinical outcomes.


Eligibility criteria:
inclusion criteria: * out-patients 18 years of age or over, who have given written informed consent to participate in the study * diagnosed with graves' disease * received radioiodine for treatment of graves' disease * had a minimum of 12 months follow-up after ri * most recent ri dose 5 years ago or less at the time of enrollment exclusion criteria: * patients unable to give informed consent * age 17 years or younger * cause of thyrotoxicosis other than graves' disease * patients who have had more than one dose of radioiodine can only be included in the study once, using data pertaining to their most recent treatment episode. * patients who might not adequately understand verbal explanations or written information given in english, or who have special communication needs

Keywords: graves' disease radioiodine thyroid hypothyroidism graves' orbitopathy
study of vitamin c, vitamin e and their combination to treat restless legs syndrome in hemodialysis patients

Conditions: Restless Legs Syndrome; Kidney Failure, Chronic

Summary: the purpose of this study is to determine whether vitamin c, vitamin e and their combination are effective in the treatment of rls in hemodialysis patients.

rls is a common problem in hemodialysis patients; 20 to 40% of hemodialysis patients suffer from rls. hemodialysis patients have a high oxidative stress status. oxidative stress has been proposed to play an important role in the pathogenesis of rls. vitamin c and vitamin e are potent antioxidant agents that have already been shown to be effective in the treatment of periodic limb movement disorder (plmd) in hemodialysis patients. plmd is closely associated with rls in hemodialysis patients. the aim of this study was to evaluate the efficacy of vitamin c, vitamin e and their combination in the treatment of rls in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * patients who fulfill restless leg syndrome international criteria(irlssg) * patients who are stable on hd without any internment illness or admission exclusion criteria: * patients who have renal stone * patients who receive medications with rls aggravating or alleviating properties

Keywords: dialysis, restless legs syndrome, ascorbic acid, vitamin e
ejection fraction of normal gall bladder on ultrasonography in patients with biliary colic: is it a predictor of cholecystectomy?

Conditions: Gall Bladder Pain; Hepatobiliary Iminodiacetic Acid; Acalculous Cholecystitis

Summary: in this study investigators aim to evaluate gallbladder ejection fraction as a predictor for cholecystectomy.

the flow of bile through the biliary system is a complex process that depends on the hormonal environment, digestive phase, and functional response of the gallbladder and sphincter of oddi to all of these factors. biliary dyskinesia is a disorder of some component of biliary part of the digestive system in which bile cannot physically flow in the proper direction through the tubular biliary tract which causes biliary colic as defined by rome iv criteria. functional causes of biliary pain, also referred to as biliary dyskinesia, are biliary hypokinesia , biliary hyperkinesia and sphincter of oddi dysfunction (sod). the exact pathology of functional biliary colic is still unknown. reviewing literature status, there is still some debate about the best method to establish the diagnosis gallbladder dyskinesia and hyperkinesia and whether or not ejection fraction is an accurate predictor of outcome. which led to difficult. biliary dyskinesia is identified through gallbladder ejection fraction (gbef), which is calculated as the flow of radioactive tracer that is ejected from the gallbladder. a gbef of \<35% is considered dyskinesia and a gbef of \<35% is considered hyperkinesia. patients considered for cck-hida (cholecystokinin hepatobiliary iminodiacetic acid) are those presenting with functional biliary pain based on the rome iv criteria. those who present with atypical pain may not need as hida (hepatobiliary iminodiacetic acid) as the presentation may be from other pathology.

Eligibility criteria:
inclusion criteria: * patients older than 14 years of age * food-related abdominal pain * normal gallbladder ultrasound (us) * gb ef 80% and greater or 35% and less on hida scan with cck injection exclusion criteria: * patients younger than 14 years old * patients with the positive us defined as the presence of gallstones, gallbladder wall thickening (\> 4 mm), pericholecystic fluid, sludge, or polyps * normal gb ef
gradual withdrawal of remifentanil infusion reduced postoperative pain and opioid requirement during breast surgery

Conditions: Pain, Postoperative

Summary: although remifentanil provides profound analgesia during operation, postoperative occurrence of hyperalgesia and tolerance after remifentanil administration could be a challenge to the postoperative pain control. evaluation of analgesia and anti-nociception during anesthesia is still a challenging issue. surgical pleth index (spi) is a non-invasive and simple access tool used to monitor autonomous nervous system during anesthesia. this technique is based on photoplethysmographic wave and heart beat analysis. spi values range between 0 (no stress) and 100 (high stress level). the purpose of this study was to determine the appropriate use of remifentanil for pain control in patients with spi.

patients were randomized into either spi-guided analgesia or standard practice (control). in both groups, anesthesia was maintained with total intravenous anaesthesia(tiva) to keep bispectral index values between 40 and 60. in the remifentanil gradual reduction group (test group), 20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes. the control group stopped remifentanil 10 minutes before the end of the operation. spi was recorded before the intubation, after the intubation, directly before the end of surgery. the number of unwanted somatic events, hemodynamics, patient-controlled analgesia(pca) consumption, narcotic analgesics consumption, and recovery times were recorded.

Eligibility criteria:
inclusion criteria: * patients who received the breast conserving surgery exclusion criteria: * patients with arrhythmia who have poor spi measurement * when the patient refused * patients with decreased renal function of cr\> 2 * surgery for more than 3 hours, surgery expected to bleed more than 500 ml
mental practice in chronic, stroke induced hemiparesis

Conditions: Hemiparesis

Summary: stroke is the leading cause of disability in the united states, producing motor impairments that compromise performance of valued activities. hemiparesis (or weakness in one arm) is particularly disabling, is the primary impairment underlying stroke-related disability, and the most frequent impairment treated by therapists in the united states. this study will test efficacy of a promising technique in reducing arm disability and increasing function, thereby improving outcomes and health, reducing care costs, for community dwelling patients with stroke-induced hemiparesis.


Eligibility criteria:
inclusion criteria: * a fugl-meyer score \> 27, which is indicative of minimal to moderate arm impairment; * stroke experienced \> 6 months prior to study enrollment; * minimal cognitive impairment, a score \> 25 on the folstein mini mental status examination (mmse); * age \> 21 years old and \< 80 years old; * have experienced one clinical stroke as verified by a physician; * discharged from all forms of physical rehabilitation targeting the affected arm. exclusion criteria: * \< 21 years old; * excessive pain in the affected hand, arm or shoulder, as measured by a score \> 5 on a 10-point visual analog scale; * excessive spasticity in the affected biceps, triceps, wrist, or fingers, as defined as a score of greater than or equal to 2 on the modified ashworth spasticity scale; * currently participating in any experimental rehabilitation or drug studies targeting ue; * mirrors movements(i.e., involuntary movements by the unaffected hand during attempts at unilateral movement by the stroke-affected hand during attempts at unilateral movement by the stroke-affected hand); * history of parietal stroke (because some data suggest that ability to estimate manual motor performance through mental imagery is disturbed after parietal lobe damage); * affected arm joint restriction that in the opinion of the investigator would hinder study participation

Keywords: mental practice group active control group
safety and biological activity of infradure biopump secreting sustained interferon in hcv patients

Conditions: Hepatitis C

Summary: this will be a phase i-ii, open-label, single center, uncontrolled, dose-escalation study. the trial will be conducted in israel at the tel aviv sourasky medical center. all subjects will receive autologous infradure biopump (micro-organ of dermis processed ex vivo transduced with genetic construct containing the gene for interferon)tissue implants intended to provide sustained production and delivery of therapeutic levels of inf for up to twenty four (24) weeks following infradure biopump implantation. follow up will continue for a total of two years post infradure biopump implantation

medgenics inc. and medgenics medical israel ltd. are developing infradure, an autologous dermal biopump capable of sustained secretion of therapeutic inf in the body, using a small tissue explant from the patient's own skin. the infradure biopump is produced from a micro-organ (mo), typically measuring 30 mm in length and 1.5-2.5 mm diameter, which is harvested directly from the patient's dermis under local anesthesia. the micro-organ can be viably maintained ex-vivo for extended periods of time under standard culture conditions. infradure biopumps, produced by ex vivo transduction of mos with helper dependent adenoviral inf vectors (hdad-inf), express and secrete inf. infradure biopump is monitored ex vivo prior to re-implantation, to attain true inf dosing. the infradure biopump is subsequently implanted subcutaneously back to the patient in order to provide continuous delivery of a known amount of inf. each implanted autologous infradure biopump remains localized under the skin, and is accessible, so that if necessary, it can be removed or ablated at any time. the entire process from harvest to implantation requires 10-14 days

Eligibility criteria:
inclusion criteria: * signed patient consent form * genotype 3 chronic hcv with detectable hcv rna * no previous treatment for hcv infection * hepatitis b and human immunodeficiency virus negative at screening visit * able and willing to follow contraception requirements * screening laboratory values, test, and physical exam within acceptable ranges exclusion criteria: * current enrollment in another investigational device or drug study * anticipated inability to complete all clinic visits and comply with study procedures * history of, or any current medical condition, which could impact the safety of the subject during the study * autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease, or other known liver disease other than hcv * alcoholism or substance abuse with \<6 documented months of sobriety * known allergy or sensitivity to interferons or ribavirin * any other condition that, in the opinion of the investigator, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study
effects of glp-1 ras on weight and metabolic indicators in obese patients

Conditions: Obesity

Summary: this studay evaluates the effect of the glucagon-like peptide-1 (glp-1) receptor agonist,including liraglutide,exenatide and exenatide microspheres for injection,in the treatment of subjects who are overweight or obese.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 65 years (to the date of screening)； 2. the newly diagnosed obese patients (bmi greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm). 3. nearly a month have not used weight-related drugs,including various weight-loss drugs,glp-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial. 4. weight stable for more than 3 months (weight fluctuations \<5%). exclusion criteria: 1. pregnant female. 2. secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others. 3. severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis. 4. combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes. 5. nearly a month had surgery, trauma, infection and so on. 6. limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators. 7. poor medication compliance or serious side effects (severe rash, syncope, etc.).
florida pancreas collaborative next generation biobank

Conditions: Pancreatic Cancer; Cancer Cachexia

Summary: the goal of this study is to partner with individuals known or suspected to have pancreatic cancer to build a biobank dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. a biobank is a resource that involves collection, processing and storage of blood, other bodily fluids, and tissue.

doctors, researchers, and patient advocates from numerous institutions throughout the state of florida have formed a partnership known as the florida pancreas collaborative. the goals of the florida pancreas collaborative team are to find better ways to diagnose and treat pancreatic cancer and improve quality of life. recent research suggests that pancreatic cancer affects people of various racial and ethnic groups differently, with some groups having more aggressive disease and a poorer prognosis than other groups. in this research study, the investigators want to partner with individuals known or suspected to have pancreatic cancer to build a 'biobank' dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. a biobank is a valuable resource that involves collection, processing, and storage of blood, other bodily fluids, and tissue (obtained during biopsy or surgery) to improve the investigator's understanding of health and disease. when combined with information and medical images obtained through routine care, the investigators will be able to investigate biological processes that may underlie differences and poor outcomes and target them with more effective therapeutic strategies tailored to the individual.

Eligibility criteria:
inclusion criteria: * 18 years of age or older. * patient presents for evaluation at a participating site with a strong clinical suspicion or diagnosis of a pancreatic cancer primary based on symptoms, imaging, biopsy, and/or blood-work and has not had treatment. * patient self-reports as non-hispanic white, african american, or hispanic. * able to understand and voluntarily sign the informed consent. * willing to complete study questionnaire(s) and donate medical images and biological specimens (including tissue and blood) obtained at the time of standard of care procedures (biopsy, surgery, and/or venipuncture) after signing the informed consent document. exclusion criteria: * no suspicion or diagnosis of pancreatic cancer. * has a diagnosis of pancreatic cancer but and has already undergone treatment (which may include surgery, chemotherapy, and/or radiation). * self-reported race/ethnicity other than non-hispanic white, african american, or hispanic. * unable to provide informed consent. * unwilling to complete study questionnaires(s) and/or donate biological specimens

Keywords: pancreas biobank quantitative imaging biomarkers health disparities
aed 3 post-approval study

Conditions: Cardiac Arrest, Out-Of-Hospital

Summary: demonstrate appropriate cpr sensor placement on pediatric and adult patients and demonstrate delivery of appropriate energy level of shocks to pediatric and adult patients.


Eligibility criteria:
inclusion criteria: * suspected out-of-hospital cardiac arrest * use of zoll aed 3 public-access defibrillator (running software v.1.03.602 or newer (us) or v. 6.03.006 or newer(ous)) with uni-padz iii * unconsciousness * absence of breathing * absence of pulse and other signs of circulation exclusion criteria: * pre-existing do not attempt resuscitation (dnar) orders * no evidence of cardiac arrest
comparison of oral and nasal tube feeding on stroke-related dysphagia

Conditions: Stroke

Summary: this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding and nasogastric tube feeding, respectively. nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

dysphagia in patients after stroke continues to be a challenge. to avoid the wound caused by gastrostomy, nasogastric tube feeding has been the mainstay of palliation, but potential side effects exist this choice. intermittent oro-esophageal tube feeding is an established modality that can be used with comprehensive rehabilitation therapy. this study reports the outcomes of intermittent oro-esophageal tube feeding and comparison with nasogastric tube feeding, including nutritional status, dysphagia, quality of life, depression, and follow-up in patients receiving comprehensive rehabilitation therapy.this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding and nasogastric tube feeding, respectively. nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * meeting the diagnostic criteria of stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * transferred out within three weeks of hospitalization in the neurology department. exclusion criteria: * complicated with other neurological diseases; * damaged mucosa or incomplete structure in nasopharynx; * tracheostomy tube plugged; * unfeasible to the support of parenteral nutrition; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
discovery: diagnostic data and genetic polymorphisms in icd patients.

Conditions: Death, Sudden, Cardiac; Ventricular Fibrillation; Tachycardia; Atrial Fibrillation; Sick Sinus Syndrome

Summary: to prospectively evaluate if the analysis of genetic polymorphisms can be used to identify patients at risk of ventricular tachycardia. to evaluate the influence of icd-based diagnostic information on the long term treatment and management of primary prevention icd-patients.

evaluate the positive predictive value of single nucleotide polymorphisms (snps) in the genes gnb3, gnas and gnaq as predictors of ventricular arrhythmia \<400 msec. 1. evaluate the positive predictive value of single nucleotide polymorphisms as predictor for death, cardiac death and atrial fibrillation/flutter in the genes gnb3, gnas, gnaq and other snps involving signal transduction components which impact on the activity of cardiac ion channels. 2. evaluate the best combination of genetic parameters, baseline data and follow-up data as predictor of primary endpoint, all cause mortality, cardiac death and atrial arrhythmia. 3. evaluate the usage of icd-system diagnostics (battery status, impedance, pacing threshold, sensing) resulting in medical consequences\*. 4. evaluate the usage of icd-based patient diagnostics (arrhythmia, iegm, heart frequency, %pacing, cardiac compass) resulting in medical consequences\*. 5. evaluate the frequency of programming changes involving af-prevention and af-therapy algorithms. 6. evaluate the frequency of pacing-parameter programming changes and the resulting medical consequences\*. * medical consequences include: hospitalization, medical interventions, medication, surgery, additional diagnostics and icd-programming changes.

Eligibility criteria:
inclusion criteria: * implantation of a market approved medtronic dual-chamber icd with long term clinical trends cardiac compass, * subjects requiring the implantation of an icd for primary prevention according to the current aha/acc/esc guidelines, * subject able to comply with the clinical investigationplan, * subject is expected to remain available for follow-up visits, * subject has signed the informed consent form within 10 days of implant, * the system implanted for this study is the first icd implant for patient. exclusion criteria: * women who are pregnant, or women of childbearing potential not on a reliable form of birth control, * subject is enrolled in a concurrent study that may confound the results of this study, * subject has a life expectancy less than two years, * subject is post heart transplant or awaiting heart transplantation, * subject is anticipated to demonstrate poor compliance, * subjects with syndromes known to be associated with ion channel pathologies such as: * long- or short-qt syndrome * brugada syndrome * catecholaminergic polymorphic ventricular tachycardia (cptv ).

Keywords: arrhythmia ventricular atrial tachycardia fibrillation flutter gnb3 gnas gnaq